Efficacy and Tolerability of Initial Triple Combination Metformin, Dapagliflozin, and Saxagliptin vs Stepwise Add-On Therapy in Drug-Naïve Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial
Diabetes Obes Metab 2024 Jun 10;[EPub Ahead of Print], NH Kim, JS Moon, YH Lee, HC Cho, SH Kwak, S Lim, MK Moon, DL Kim, TH Kim, E Ko, J Lee, SG KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.